STOCK TITAN
  1. Home
  2. Sec-filings
  3. AKTX
  4. [Form 4] Akari Therapeutics Plc Insider Trading Activity

Akari Therapeutics (AKTX) CEO granted stock options tied to ADS and financings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Akari Therapeutics CEO Abizer Gaslightwala reported new stock option awards. On April 1, 2026 he was granted options over 15,563 American Depositary Shares at an exercise price of $14.63 per ADS and options over 5,500 ADS at $4.64 per ADS. Each ADS represents 80,000 ordinary shares. These awards were compensation-related grants rather than open-market share purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Gaslightwala Abizer
Role CEO
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 5,500 $0.00 --
Grant/Award Stock Option (Right to Buy) 15,563 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 5,500 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 15,563 ADS CEO stock option grant at $14.63 exercise price
Exercise price $14.63 per ADS Option over 15,563 ADS, expires June 24, 2036
Second option grant size 5,500 ADS CEO stock option grant at $4.64 exercise price
Exercise price (second grant) $4.64 per ADS Option over 5,500 ADS, expires April 1, 2036
Underlying ordinary share ratio 80,000 ordinary shares per ADS Footnote describing ADS-to-ordinary share relationship
Financing threshold for vesting $15,000,000 Qualified financings required for full option vesting
Completed qualified financing $5,500,000 Triggered vesting of 5,500 ADS under April 1, 2026 option
Par value per ordinary share $0.000000005 Ordinary share par value referenced in option footnote
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
American Depositary Shares financial
"underlying_security_title: American Depositary Shares representing Ordinary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
qualified financings financial
"vests in three installments based on the closing of qualified financings"
gross proceeds financial
"qualified financings of at least $15,000,000 in gross proceeds"
The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.
par value financial
"ordinary shares with a par value of $0.000000005 per ordinary share"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gaslightwala Abizer
(Last)(First)(Middle)
C/O AKARI THERAPEUTICS PLC
401 EAST JACKSON STREET, SUITE 3300
(Street)
TAMPA FLORIDA 33602
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Akari Therapeutics Plc [ AKTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$4.6406/24/2026A5,50006/24/202604/01/2036American Depositary Shares representing Ordinary Shares5,500$05,500(1)D
Stock Option (Right to Buy)$14.6306/24/2026A15,56306/24/202606/24/2036American Depositary Shares representing Ordinary Shares15,563$015,563D
Explanation of Responses:
1. On April 1, 2026, the reporting person was granted an option to purchase 15,000 American Depositary Shares, with each American Depositary Share representing 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The option vests in three installments based on the closing of qualified financings of at least $15,000,000 in gross proceeds on or before June 30, 2026. The Issuer closed a qualified financing of $5,500,000, resulting in the vesting of the option as to 5,500 American Depositary Shares.
/s/ Abizer Gaslightwala06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Akari Therapeutics (AKTX) CEO Abizer Gaslightwala report on this Form 4?

The Form 4 shows Abizer Gaslightwala received stock option awards as compensation. He was granted options over 15,563 and 5,500 American Depositary Shares, with no open-market share purchases or sales reported.

How many Akari Therapeutics (AKTX) stock options did the CEO receive?

Abizer Gaslightwala received options over 15,563 American Depositary Shares and a separate grant over 5,500 ADS. Each option gives the right to buy one ADS under the specified exercise price and expiry terms in the filing.

What are the exercise prices and expirations of the Akari (AKTX) CEO’s new options?

One option grant covers 15,563 ADS at $14.63 per ADS expiring on June 24, 2036. The other covers 5,500 ADS at $4.64 per ADS, expiring on April 1, 2036, according to the reported terms.

Does the Akari Therapeutics (AKTX) Form 4 show the CEO buying or selling shares?

The filing does not show any open-market buying or selling of shares. It reports compensation-related acquisitions of stock options, categorized as grants or awards, rather than discretionary purchases or sales.

What does each American Depositary Share (ADS) of Akari Therapeutics (AKTX) represent?

Each American Depositary Share mentioned in the CEO’s option grant represents 80,000 ordinary shares with a par value of $0.000000005 per ordinary share, as described in the footnote to the reported option award.

How were the Akari (AKTX) CEO’s options linked to company financings?

A footnote explains a 15,000 ADS option grant vests in installments based on qualified financings of at least $15,000,000. A completed $5,500,000 financing caused vesting of 5,500 ADS under that option grant.